Merck & Co. – Revenue by Segment

Quarterly charts & data from official filings

Timeframe

Revenue by segment

Revenue by segmentTable view

Earnings release date
Pharmaceutical
Animal Health
Other revenues
Total
Earnings release date:30 Apr. 26
Pharmaceutical:
14,349,000,000 $-3.3%
Animal Health:
1,791,000,000 $+19.0%
Other revenues:
146,000,000 $+180.8%
Total:
16,286,000,000 $-0.7%
Earnings release date:03 Feb. 26
Pharmaceutical:
14,843,000,000 $-4.9%
Animal Health:
1,505,000,000 $-6.8%
Other revenues:
52,000,000 $+4.0%
Total:
16,400,000,000 $-5.1%
Earnings release date:30 Oct. 25
Pharmaceutical:
15,611,000,000 $+11.1%
Animal Health:
1,615,000,000 $-1.9%
Other revenues:
50,000,000 $-54.5%
Total:
17,276,000,000 $+9.3%
Earnings release date:29 Jul. 25
Pharmaceutical:
14,050,000,000 $+3.0%
Animal Health:
1,646,000,000 $+3.7%
Other revenues:
110,000,000 $-63.7%
Total:
15,806,000,000 $+1.8%
Earnings release date:24 Apr. 25
Pharmaceutical:
13,638,000,000 $-2.9%
Animal Health:
1,588,000,000 $+13.7%
Other revenues:
303,000,000 $+63.8%
Total:
15,529,000,000 $-0.6%
Earnings release date:04 Feb. 25
Pharmaceutical:
14,042,000,000 $-6.0%
Animal Health:
1,397,000,000 $-6.1%
Other revenues:
185,000,000 $-18.5%
Total:
15,624,000,000 $-6.2%
Earnings release date:31 Oct. 24
Pharmaceutical:
14,943,000,000 $+3.7%
Animal Health:
1,487,000,000 $+0.3%
Other revenues:
227,000,000 $+2.3%
Total:
16,657,000,000 $+3.4%
Earnings release date:30 Jul. 24
Pharmaceutical:
14,408,000,000 $+2.9%
Animal Health:
1,482,000,000 $-1.9%
Other revenues:
222,000,000 $-14.0%
Total:
16,112,000,000 $+2.1%
Earnings release date:25 Apr. 24
Pharmaceutical:
14,006,000,000 $+6.6%
Animal Health:
1,511,000,000 $+18.2%
Other revenues:
258,000,000 $+22.3%
Total:
15,775,000,000 $+7.8%
Earnings release date:01 Feb. 24
Pharmaceutical:
13,141,000,000 $-7.9%
Animal Health:
1,278,000,000 $-8.7%
Other revenues:
211,000,000 $-29.4%
Total:
14,630,000,000 $-8.3%
Earnings release date:26 Oct. 23
Pharmaceutical:
14,263,000,000 $+6.0%
Animal Health:
1,400,000,000 $-3.8%
Other revenues:
299,000,000 $+145.1%
Total:
15,962,000,000 $+6.2%
Earnings release date:01 Aug. 23
Pharmaceutical:
13,457,000,000 $+5.8%
Animal Health:
1,456,000,000 $-2.3%
Other revenues:
122,000,000 $-55.6%
Total:
15,035,000,000 $+3.8%
Earnings release date:27 Apr. 23
Pharmaceutical:
12,721,000,000 $+4.4%
Animal Health:
1,491,000,000 $+21.2%
Other revenues:
275,000,000 $-34.5%
Total:
14,487,000,000 $+4.8%
Earnings release date:02 Feb. 23
Pharmaceutical:
12,180,000,000 $-6.0%
Animal Health:
1,230,000,000 $-10.3%
Other revenues:
420,000,000 $-32.8%
Total:
13,830,000,000 $-7.5%
Earnings release date:27 Oct. 22
Pharmaceutical:
12,963,000,000 $+1.6%
Animal Health:
1,371,000,000 $-6.5%
Other revenues:
625,000,000 $+68.9%
Total:
14,959,000,000 $+2.5%
Earnings release date:28 Jul. 22
Pharmaceutical:
12,756,000,000 $
Animal Health:
1,467,000,000 $
Other revenues:
370,000,000 $
Total:
14,593,000,000 $

Expenses

ExpensesTable view

Earnings release date
Cost of sales
Selling, general and administrative
Research and development
Restructuring costs
Total
Earnings release date:30 Apr. 26
Cost of sales:
4,195,000,000 $-24.4%
Selling, general and administrative:
2,700,000,000 $-6.8%
Research and development:
12,592,000,000 $+224.0%
Restructuring costs:
195,000,000 $-8.5%
Total:
19,682,000,000 $+56.9%
Earnings release date:03 Feb. 26
Cost of sales:
5,551,000,000 $+44.0%
Selling, general and administrative:
2,898,000,000 $+10.1%
Research and development:
3,886,000,000 $-8.2%
Restructuring costs:
213,000,000 $+353.2%
Total:
12,548,000,000 $+16.5%
Earnings release date:30 Oct. 25
Cost of sales:
3,855,000,000 $+8.4%
Selling, general and administrative:
2,633,000,000 $-0.6%
Research and development:
4,234,000,000 $+4.6%
Restructuring costs:
47,000,000 $-91.6%
Total:
10,769,000,000 $-0.4%
Earnings release date:29 Jul. 25
Cost of sales:
3,557,000,000 $+4.0%
Selling, general and administrative:
2,649,000,000 $+3.8%
Research and development:
4,048,000,000 $+11.8%
Restructuring costs:
560,000,000 $+711.6%
Total:
10,814,000,000 $+11.9%
Earnings release date:24 Apr. 25
Cost of sales:
3,419,000,000 $-10.7%
Selling, general and administrative:
2,552,000,000 $-10.9%
Research and development:
3,621,000,000 $-21.0%
Restructuring costs:
69,000,000 $+35.3%
Total:
9,661,000,000 $-14.7%
Earnings release date:04 Feb. 25
Cost of sales:
3,828,000,000 $-6.2%
Selling, general and administrative:
2,864,000,000 $+4.9%
Research and development:
4,585,000,000 $-21.8%
Restructuring costs:
51,000,000 $-8.9%
Total:
11,328,000,000 $-11.0%
Earnings release date:31 Oct. 24
Cost of sales:
4,080,000,000 $+8.9%
Selling, general and administrative:
2,731,000,000 $-0.3%
Research and development:
5,862,000,000 $+67.5%
Restructuring costs:
56,000,000 $-30.0%
Total:
12,729,000,000 $+26.5%
Earnings release date:30 Jul. 24
Cost of sales:
3,745,000,000 $+5.8%
Selling, general and administrative:
2,739,000,000 $+10.3%
Research and development:
3,500,000,000 $-12.3%
Restructuring costs:
80,000,000 $-35.0%
Total:
10,064,000,000 $-0.7%
Earnings release date:25 Apr. 24
Cost of sales:
3,540,000,000 $-9.5%
Selling, general and administrative:
2,483,000,000 $-11.4%
Research and development:
3,992,000,000 $-58.5%
Restructuring costs:
123,000,000 $-51.8%
Total:
10,138,000,000 $-38.9%
Earnings release date:01 Feb. 24
Cost of sales:
3,911,000,000 $-8.3%
Selling, general and administrative:
2,804,000,000 $+11.3%
Research and development:
9,628,000,000 $+191.1%
Restructuring costs:
255,000,000 $+102.4%
Total:
16,598,000,000 $+62.5%
Earnings release date:26 Oct. 23
Cost of sales:
4,264,000,000 $+6.0%
Selling, general and administrative:
2,519,000,000 $-6.8%
Research and development:
3,307,000,000 $-75.2%
Restructuring costs:
126,000,000 $-16.6%
Total:
10,216,000,000 $-49.4%
Earnings release date:01 Aug. 23
Cost of sales:
4,024,000,000 $+2.5%
Selling, general and administrative:
2,702,000,000 $+9.0%
Research and development:
13,321,000,000 $+211.5%
Restructuring costs:
151,000,000 $+125.4%
Total:
20,198,000,000 $+87.9%
Earnings release date:27 Apr. 23
Cost of sales:
3,926,000,000 $+1.2%
Selling, general and administrative:
2,479,000,000 $-7.7%
Research and development:
4,276,000,000 $+13.3%
Restructuring costs:
67,000,000 $+36.7%
Total:
10,748,000,000 $+3.4%
Earnings release date:02 Feb. 23
Cost of sales:
3,881,000,000 $-1.3%
Selling, general and administrative:
2,687,000,000 $+6.6%
Research and development:
3,775,000,000 $-14.2%
Restructuring costs:
49,000,000 $-47.9%
Total:
10,392,000,000 $-5.1%
Earnings release date:27 Oct. 22
Cost of sales:
3,934,000,000 $-6.7%
Selling, general and administrative:
2,520,000,000 $+0.3%
Research and development:
4,399,000,000 $+57.2%
Restructuring costs:
94,000,000 $-33.8%
Total:
10,947,000,000 $+13.2%
Earnings release date:28 Jul. 22
Cost of sales:
4,216,000,000 $
Selling, general and administrative:
2,512,000,000 $
Research and development:
2,798,000,000 $
Restructuring costs:
142,000,000 $
Total:
9,668,000,000 $

Profitability

ProfitabilityTable view

Earnings release date
Net income (shareholders)
Earnings release date:30 Apr. 26
Net income (shareholders):
-4,240,000,000 $-243.1%
Earnings release date:03 Feb. 26
Net income (shareholders):
2,963,000,000 $-48.8%
Earnings release date:30 Oct. 25
Net income (shareholders):
5,785,000,000 $+30.7%
Earnings release date:29 Jul. 25
Net income (shareholders):
4,427,000,000 $-12.8%
Earnings release date:24 Apr. 25
Net income (shareholders):
5,079,000,000 $+35.7%
Earnings release date:04 Feb. 25
Net income (shareholders):
3,743,000,000 $+18.6%
Earnings release date:31 Oct. 24
Net income (shareholders):
3,157,000,000 $-42.1%
Earnings release date:30 Jul. 24
Net income (shareholders):
5,455,000,000 $+14.6%
Earnings release date:25 Apr. 24
Net income (shareholders):
4,762,000,000 $+488.4%
Earnings release date:01 Feb. 24
Net income (shareholders):
-1,226,000,000 $-125.8%
Earnings release date:26 Oct. 23
Net income (shareholders):
4,745,000,000 $+179.4%
Earnings release date:01 Aug. 23
Net income (shareholders):
-5,975,000,000 $-311.8%
Earnings release date:27 Apr. 23
Net income (shareholders):
2,821,000,000 $-6.5%
Earnings release date:02 Feb. 23
Net income (shareholders):
3,017,000,000 $-7.1%
Earnings release date:27 Oct. 22
Net income (shareholders):
3,248,000,000 $-17.6%
Earnings release date:28 Jul. 22
Net income (shareholders):
3,944,000,000 $

Profit margin (shareholders) in %

Profit margin (shareholders) in %Table view

Earnings release date
Profit Margin (shareholders)
Earnings release date:30 Apr. 26
Profit Margin (shareholders):
-26.03 %-44.1 pp
Earnings release date:03 Feb. 26
Profit Margin (shareholders):
18.07 %-15.4 pp
Earnings release date:30 Oct. 25
Profit Margin (shareholders):
33.49 %+5.5 pp
Earnings release date:29 Jul. 25
Profit Margin (shareholders):
28.01 %-4.7 pp
Earnings release date:24 Apr. 25
Profit Margin (shareholders):
32.71 %+8.7 pp
Earnings release date:04 Feb. 25
Profit Margin (shareholders):
23.96 %+5.0 pp
Earnings release date:31 Oct. 24
Profit Margin (shareholders):
18.95 %-14.9 pp
Earnings release date:30 Jul. 24
Profit Margin (shareholders):
33.86 %+3.7 pp
Earnings release date:25 Apr. 24
Profit Margin (shareholders):
30.19 %+38.6 pp
Earnings release date:01 Feb. 24
Profit Margin (shareholders):
-8.38 %-38.1 pp
Earnings release date:26 Oct. 23
Profit Margin (shareholders):
29.73 %+69.5 pp
Earnings release date:01 Aug. 23
Profit Margin (shareholders):
-39.74 %-59.2 pp
Earnings release date:27 Apr. 23
Profit Margin (shareholders):
19.47 %-2.3 pp
Earnings release date:02 Feb. 23
Profit Margin (shareholders):
21.81 %+0.1 pp
Earnings release date:27 Oct. 22
Profit Margin (shareholders):
21.71 %-5.3 pp
Earnings release date:28 Jul. 22
Profit Margin (shareholders):
27.03 %